SPHERA Global Healthcare

SPHERA targets both pre-approval and marketed pharmaceutical products, as well as medical devices with demonstrated clinical utility and revenue traction. The firm evaluates single-asset opportunities and portfolios of healthcare receivables. Therapeutic areas of interest have historically included oncology, rare disease, cardiovascular, and central nervous system categories, though the firm is not limited to any single indication. Minimum transaction sizes are not publicly disclosed.

Investment decisions are led by CEO Rama Rao and Executive Chairman Richard Gough, both of whom have backgrounds spanning pharmaceutical operations and structured healthcare finance. COO and CFO Niall Dickson oversees financial operations and portfolio management. The firm operates with a lean senior team, which keeps underwriting concentrated in principals with direct experience across drug development, regulatory pathways, and intellectual-property valuation.

SPHERA executes direct transactions exclusively — it does not function as a fund-of-funds or allocate capital to third-party managers. The firm raises capital on a deal-by-deal basis or through dedicated vehicles and applies it directly to the royalty or credit instruments it structures. This direct model gives SPHERA full control over negotiation, diligence, and ongoing monitoring of each asset.

SPHERA stays within healthcare and life sciences, avoiding generalist credit, technology, real estate, and other non-healthcare sectors. Within healthcare, the firm has not publicly indicated participation in provider-focused buyouts, hospital operations, or health insurance businesses. Its mandate is deliberately narrow: royalty and credit instruments tied to pharmaceutical and medical-device revenue streams.